Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer

Journal of Pathology

Volumn 183, Issue 2, 1997, Pages 222-227

  Müller, Wolfram ^a   Schneiders, Anke ^a   Heider, Karl Heinz ^b   Meier, Stephanie ^a   Hommel, Gerhard ^c   Gabbert, Helmut E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Bender and Co GesmbH   (Austria)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

CD44; Gastric cancer; Immunohistochemistry; Prognosis

Indexed keywords

HERMES ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER SURVIVAL; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; STOMACH CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; ANTIGENS, CD44; ANTIGENS, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GASTRIC MUCOSA; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 1842337425     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199710)183:2<222::AID-PATH923>3.0.CO;2-C     Document Type: Article

References (27)

1. Aruffo A, Stamenkovic I, Melnick M, Underbill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61: 1303-1313.
2. St. John T, Meyer J, Idzerda R, Gallatin WM. Expression of CD44 confers a new adhesive phenotype on transfected cells. Cell 1990; 60: 45-52.
3. Faassen AE, Schrager A, Klein DJ, Oegema TR, Couchman JR, McCarthy JB. A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion. J Cell Biol 1992; 116: 512-531.
4. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bel JI, Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89: 12160-12164.
5. Günthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
6. Terpe HJ, Koopmann R, Imhof B, Günthert U. Expression of integrins and CD44 isoforms in non-Hodgkin lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas. J Pathol 1994; 174: 89-100.
7. Joensuu H, Klemi PJ, Toikkanen S, Jalkanen S. Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 1993; 143: 867-874.
8. Dall P, Heider KH, Sinn HP, et al. Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer 1995; 60: 471-477.
9. Kaufmann M, Heider KH, Sinn HP, Von Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995; 345: 615-619.
10. Wielenga VJM, Heider KH, Offerhaus GJA. et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumour progression. Cancer Res 1993; 53: 4754-1756.
11. Washington K, Gottfried MR, Telen MJ. Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. Hum Pathol 1994; 25: 1043-1049.
12. Hong RL, Lee WJ, Shun CT, Chu JS, Chen YC. Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas. Oncology 1995; 52: 334-339.
13. Heider KH, Dämmrich J, Skroch-Angel P, et al. Differential expression of CD44 splice variants in intestinal and diffuse type human gastric carcinoma and normal gastric mucosa. Cancer Res 1993; 53: 4197-4203.
14. Mayer B, Jauch KW, Günthert U, et al. De nova expression of CD44 and survival in gastric cancer. Lancet 1993; 342: 1019-1022.
15. Oota K, Sobin LH. Histological Typing of Gastric and Oesophageal Tumours. International Histological Classification of Tumours, 18. Geneva: WHO, 1977.
16. Lauren P. The two histological main types of gastric carcinomas: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Immunol Scand 1965; 64: 31-49.
17. International Union Against Cancer. TNM Classification of Malignant Tumours, 4th edn. Berlin: Springer-Verlag, 1987; 43-46.
18. Gabbert HE, Meier S, Gerharz CD, Hommel G. Incidence and prognostic significance of vascular invasion in 529 gastric cancer patients. Int J Cancer 1991; 49: 203-207.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
20. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Data. New York: Wiley, 1980.
21. Reber S, Matzku S, Günthert U, Ponta H, Herrlich P, Zöller M. Retardation of metastatic tumor growth after immunization with metastasis-specific monoclonal antibodies. Int J Cancer 1990; 46: 919-927.
22. Seiter S, Arch R, Komitowski D, et al. Prevention of tumour metastasis formation by anti-variant CD44. J Exp Med 1993; 177: 443-455.
23. Matsumara Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992; 340: 1053-1058.
24. Terpe HJ, Störkel S, Zimmer U, et al. Expression of CD44 isoforms in renal cell tumours. Am J Pathol 1996; 148: 453-463.
25. Friedrichs K, Franke F, Lisboa BW, et al. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995; 55: 5424-5433.
26. Koretz K, Möller P, Lehnert T, Hinz U, Otto HF, Herfarth C. Effect of CD44v6 on survival in colorectal carcinoma (Letter). Lancet 1995; 345: 327-328.
27. Finke LH, Terpe HJ, Zörb C, Haensch W, Schlag PM. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins (Letter). Lancet 1995; 345: 583.